Better Buy: Johnson & Johnson vs. Merck
This big pharma claims one of the hottest cancer drugs around. But it also faces challenges for some of its biggest-selling drugs. Which big pharma is it?
Actually, it's two: Johnson & Johnson (NYSE: JNJ) and Merck (NYSE: MRK).
These companies are similar in several ways. However, Johnson & Johnson stock is up big in 2017, while Merck stock has lost ground this year. Will J&J continue to be the better pick, or will Merck roar back? Here's how these pharma stocks compare.
Source: Fool.com
Johnson & Johnson Aktie
219,40 €
-0,77 %
Johnson & Johnson als klarer Gewinner: Nur Buy-Einschätzungen, keine Sell-Einschätzungen.
Das Community-Kursziel von 227 € für Johnson & Johnson deutet auf ein leicht positives Wachstumspotenzial gegenüber 219.4 € hin.
